AN2 Therapeutics, Inc.

ANTX · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$51,321-$64,732-$40,956-$21,543
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$8,338$8,412$4,391$974
Change in WC-$2,995$5,834$3,718$32
Other Non-Cash-$3,279-$2,802-$615$53
Operating Cash Flow-$49,257-$53,288-$33,462-$20,484
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$46,751-$132,178-$93,836-$77,274
Inv. Sales/Matur.$101,340$88,900$72,065$27,250
Other Inv. Act.$0$0$0$0
Investing Cash Flow$54,589-$43,278-$21,771-$50,024
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$372$84,529$70,366$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$465-$11$78,535
Financing Cash Flow$372$84,994$70,355$78,535
Forex Effect$0$0$0$0
Net Chg. in Cash$5,704-$11,572$15,122$8,027
Supplemental Information
Beg. Cash$15,647$27,219$12,097$4,070
End Cash$21,351$15,647$27,219$12,097
Free Cash Flow-$49,257-$53,288-$33,462-$20,484